APA (7th ed.) Citation

KL, P., N, S., JH, J., PG, G., SR, K., NL, B., . . . S, P. (2015). Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(12), 1340. https://doi.org/10.1200/JCO.2014.56.2439

Chicago Style (17th ed.) Citation

KL, Pogue-Geile, et al. "Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit from Adjuvant Trastuzumab in the NSABP B-31 Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 33, no. 12 (2015): 1340. https://doi.org/10.1200/JCO.2014.56.2439.

MLA (9th ed.) Citation

KL, Pogue-Geile, et al. "Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit from Adjuvant Trastuzumab in the NSABP B-31 Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 33, no. 12, 2015, p. 1340, https://doi.org/10.1200/JCO.2014.56.2439.